Learnings from the Australasian clinical guidelines

Male infertility affects approximately 7% of men globally and contributes to roughly half of all infertility cases. Research suggests infertility affects around one in every six couples worldwide, with male factors the sole cause in around 20–30% of cases and a combination of male and female factors responsible in a further 20–30% of cases. As longevity medicine practitioners increasingly encounter men seeking to optimize reproductive health well into their 40s and beyond, understanding evidence-based management of male infertility becomes essential. This review synthesizes current clinical guidelines with practical applications for the aging male patient.

This article is based on the first Australasian Clinical guidelines for the management of male infertility RACGP - Male infertility guidelines launched

Key Take Home Points  

  • an initial evaluation of male fertility should include a reproductive and medical history, physical (including scrotal) examination and semen analysis
  • a concurrent evaluation of the female partner takes place
  • semen analysis is offered according to current WHO Laboratory Manual for the Examination and Processing of Human Semen. If the first analysis is abnormal, a second semen analysis is performed around six weeks later, or longer if clinically indicated.

Recommendations 

  • The female partner should undergo a parallel assessment of her fertility status, including ovarian reserve, as this might influence clinical decision-making regarding the timing and type of intervention (such as assisted reproductive technologies versus surgical intervention)
  • Men with one or more abnormal semen parameters or those with suspected male factor infertility should be further evaluated by a specialist in male reproduction where available
  • Do not perform antisperm antibody testing in the initial evaluation of male infertility
  • Advise all men to undertake monthly testicular self-examination until the age of 55
  • Do not routinely perform scrotal ultrasound in the initial evaluation

Initial Assessment Framework

The male infertility evaluation begins with a thorough history and physical exam.

History covers:

  • Reproductive: Infertility duration, prior conceptions, intercourse frequency/timing, and female partner status
  • Medical/Surgical: History of cryptorchidism, torsion, trauma, STIs, systemic diseases (e.g., diabetes, thyroid), and past surgeries (hernia, bladder neck, retroperitoneal). A review of medications is essential (testosterone, anabolic steroids, finasteride, SSRIs, calcium channel blockers, chemotherapy).
  • Lifestyle/Environmental: Occupational exposures (heat, radiation, heavy metals, pesticides), substance use (tobacco, alcohol, cannabis, steroids), exercise/heat exposure (saunas, cycling), stress, and sleep.

Physical Exam must assess secondary sexual traits, gynecomastia, testicular volume (normal >15mL), consistency, and varicocele. A digital rectal exam may be required.

Laboratory Evaluation

  • Semen Analysis requires two tests, 2-3 weeks apart (up to 3 months), after 2-7 days of abstinence. WHO 2021 reference values: Volume >1.4 mL, Concentration >16 M/mL, Total sperm 39 M, Motility 30% progressive or42% total, Morphology 4% normal, Vitality 54% live.

  • Hormonal Assessment is for sperm concentration $<10$ M/mL, abnormal sexual/physical exam, or suspected endocrinopathy. Essential hormones: FSH (elevated suggests primary testicular failure), Total testosterone (morning sample), LH (differentiates primary/secondary hypogonadism), and Prolactin (if low libido, ED, or pituitary dysfunction suspected).

  • Advanced Testing: Genetic Testing (Karyotype, Y chromosome microdeletion, CFTR) is for Azoospermia or severe Oligozoospermia $(<5$ M/mL). Specialized Tests include Post-ejaculatory urinalysis (for retrograde ejaculation), Testicular biopsy (obstructive vs. non-obstructive azoospermia), Scrotal ultrasound (varicocele, masses, obstruction), and Transrectal ultrasound (ejaculatory duct obstruction).

Common Etiologies and Management

Male Factor Infertility Management

1. Varicocele (40% Primary Infertility)

Dilated pampiniform plexus.

Treatment Indications: Palpable varicocele, abnormal semen, progressive testicular decline, or normal/treatable female partner factors.

Approach: Surgical varicocelectomy (microsurgical, laparoscopic, open) or embolization. Improves semen (60-80%) and pregnancy rates (30-40%). Meta-analysis OR 2.39.

2. Idiopathic Infertility (25-30%)

No identifiable cause. Empiric medical management is possible but evidence is limited.

Interventions: Antioxidants (CoQ10, Vit E, Vit C, Selenium), Lifestyle (weight loss if BMI >30, stop smoking, moderate alcohol), Heat Avoidance (laptops, hot tubs, tight underwear).

3. Hypogonadotropic Hypogonadism

Secondary hypogonadism (pituitary/hypothalamic dysfunction); requires hormonal therapy, not testosterone replacement.

Treatment: hCG monotherapy (1500-2000 IU SC 3x weekly); add recombinant FSH (75-150 IU 3x weekly) if no response after 3-6 months; Pulsatile GnRH for hypothalamic causes (rare). Sperm production typically occurs within 6-12 months, sometimes up to 24 months.

4. Obstructive Azoospermia (40% of Azoospermia)

Physical blockage of sperm transport.

Management: Vasectomy reversal (Vasovasostomy: 85-97% patency, 30-75% pregnancy); Surgical reconstruction (ejaculatory duct obstruction, congenital absence of vas deferens); Sperm retrieval (TESE/microTESE) with IVF/ICSI.

5. Testosterone/Anabolic Steroid-Induced Azoospermia

Exogenous steroids suppress the HPG axis, causing reversible (but possibly prolonged) azoospermia.

Recovery Protocol: Discontinue steroids immediately. hCG therapy (3000 IU SC 3x weekly for 3-6 months). Add clomiphene or anastrozole if inadequate response. Consider FSH if no sperm after 6 months. Monitor semen Q3 months. Recovery takes 6-24 months; may be longer or incomplete with long-term high-dose use.

6. Ejaculatory Dysfunction

Retrograde Ejaculation: Sperm flows into the bladder. Treat with Alpha-adrenergic agonists (pseudoephedrine, imipramine) to restore bladder neck closure, or sperm harvest from post-ejaculatory urine for ART.

Anejaculation: Failure to ejaculate despite orgasm. Treat with Penile Vibratory Stimulation (PVS) for spinal cord injuries, or Electroejaculation (EEJ) under anesthesia if PVS fails.

Longevity Medicine Considerations

The Aging Male and Fertility

While men maintain fertility potential throughout life, semen parameters decline with age:

  • Sperm concentration decreases approximately 0.7% per year after age 35
  • Motility declines 0.6-0.9% annually
  • DNA fragmentation increases with paternal age
  • Time to conception lengthens significantly after male age 40

Clinical Implications: Men pursuing later-life fatherhood benefit from early fertility assessment and proactive intervention. Consider sperm banking before age 40 for men planning delayed reproduction.

Metabolic Health Integration

Metabolic syndrome directly impairs male fertility through multiple mechanisms:

  • Aromatization of testosterone to estrogen in adipose tissue
  • Insulin resistance affecting Sertoli cell function
  • Oxidative stress damaging sperm DNA
  • Erectile dysfunction from endothelial dysfunction

Optimization Strategy: Weight loss of just 5-10% in obese men improves testosterone levels by 50-100 ng/dL and significantly improves semen parameters. This represents first-line intervention before pharmacotherapy.

Medication Review Critical

Many medications prescribed in longevity medicine practices affect fertility:

  • Finasteride/dutasteride: May reduce semen volume and count, though data are mixed
  • SSRIs/SNRIs: Impair libido and cause ejaculatory dysfunction
  • Testosterone replacement: Completely contraindicated when fertility desired
  • Metformin: Generally safe and may improve insulin resistance-related infertility
  • Statins: Minimal to no impact on fertility despite theoretical concerns

Assisted Reproductive Technology (ART) Considerations

When natural conception fails despite optimization, ART provides effective options:

Intrauterine Insemination (IUI)

  • Success rate: 10-20% per cycle
  • Best for mild male factor infertility (concentration >10 million/mL)
  • Typically attempt 3-6 cycles before escalating

In Vitro Fertilization (IVF)

  • Success rate: 30-50% per cycle (age-dependent)
  • Appropriate for moderate male factor or failed IUI

Intracytoplasmic Sperm Injection (ICSI)

  • Success rate: Similar to conventional IVF
  • Required for severe oligozoospermia, obstructive azoospermia with sperm retrieval
  • Single sperm injected directly into oocyte

Evidence-Based Supplement Protocols

While data quality varies, certain supplements show consistent benefit:

Strong Evidence:

  • Coenzyme Q10: 200-300 mg daily for 3-6 months improves sperm concentration and motility
  • L-carnitine: 2-3 grams daily improves sperm motility and morphology
  • Vitamin D: Correct deficiency (<30 ng/mL) with 2000-5000 IU daily; vitamin D receptors present in sperm

Moderate Evidence:

  • Zinc: 220 mg zinc sulfate daily (particularly if deficient)
  • Folate: 5 mg daily, especially with methylation variants
  • N-acetylcysteine: 600 mg daily as antioxidant

Emerging Evidence:

  • Omega-3 fatty acids: 1-2 grams daily may improve sperm quality
  • Ashwagandha: 300-500 mg standardized extract may improve sperm parameters and testosterone

Practice Guidelines Summary

Major international guidelines (AUA, EAU, ASRM) converge on these principles:

  1. Couple-based approach: Evaluate both partners simultaneously
  2. Minimum two semen analyses: Allow adequate time between tests
  3. Hormone testing: For concentration <10 million/mL or clinical indicators
  4. Genetic testing: For severe oligozoospermia or azoospermia
  5. Lifestyle modification: First-line intervention for all patients
  6. Varicocele repair: For palpable varicocele with abnormal parameters
  7. Time-sensitive referral: Consider ART referral if female partner >35 years
  8. Avoid empiric testosterone: Absolute contraindication when fertility desired

When to Refer

Reproductive urology/andrology referral indicated for:

  • Azoospermia or severe oligozoospermia (<5 million/mL)
  • Palpable varicocele with abnormal semen parameters
  • History of cryptorchidism, testicular surgery, or trauma
  • Abnormal hormonal profile requiring specialist interpretation
  • Consideration of surgical sperm retrieval
  • Failed initial interventions after 6-12 months

Conclusion

Male infertility management requires systematic evaluation, targeted intervention, and often multidisciplinary collaboration. For longevity medicine practitioners, integrating fertility assessment into comprehensive male health optimization allows early identification and treatment of reversible factors. The intersection of metabolic health, hormonal optimization, and fertility preservation represents an opportunity to provide substantial value to male patients pursuing extended healthspan and delayed reproduction.

Most importantly, avoid testosterone replacement therapy in any man desiring current or future fertility without first implementing fertility preservation strategies. This single intervention prevents a common and devastating iatrogenic cause of male infertility in our patient population.